Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
UCD Conway Institute & School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland.
J Physiol. 2018 Sep;596(17):3899-3913. doi: 10.1113/JP275327. Epub 2018 Mar 5.
The hypoxia-inducible factor (HIF) co-ordinates the adaptive transcriptional response to hypoxia in metazoan cells. The hypoxic sensitivity of HIF is conferred by a family of oxygen-sensing enzymes termed HIF hydroxylases. This family consists of three prolyl hydroxylases (PHD1-3) and a single asparagine hydroxylase termed factor inhibiting HIF (FIH). It has recently become clear that HIF hydroxylases are functionally non-redundant and have discrete but overlapping physiological roles. Furthermore, altered abundance or activity of these enzymes is associated with a number of pathologies. Pharmacological HIF-hydroxylase inhibitors have recently proven to be both tolerated and therapeutically effective in patients. In this review, we focus on the physiology, pathophysiology and therapeutic potential of the PHD1 isoform, which has recently been implicated in diseases including inflammatory bowel disease, ischaemia and cancer.
缺氧诱导因子 (HIF) 协调后生动物细胞对缺氧的适应性转录反应。HIF 的缺氧敏感性由一类称为 HIF 羟化酶的氧感应酶家族赋予。该家族由三种脯氨酰羟化酶(PHD1-3)和一种称为 HIF 抑制因子的天冬酰胺羟化酶组成。最近已经清楚的是,HIF 羟化酶在功能上是不可替代的,并且具有不同但重叠的生理作用。此外,这些酶的丰度或活性的改变与许多病理学有关。最近的研究证明,这些酶的药理学抑制剂在患者中既耐受又具有治疗效果。在这篇综述中,我们专注于 PHD1 同工型的生理学、病理生理学和治疗潜力,该同工型最近与包括炎症性肠病、缺血和癌症在内的疾病有关。